Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway
Wei Zhang, Ankur S Bhagwath, Zeeshan Ramzan, Taylor A Williams, Indhumathy Subramaniyan, Vindhya Edpuganti, Raja Reddy Kallem, Kerry B Dunbar, Peiguo Ding, Ke Gong, Samuel A Geurkink, Muhammad S Beg, James Kim, Qiuyang Zhang, Amyn A Habib, Sung-Hee Choi, Ritu Lapsiwala, Gayathri Bhagwath, Jonathan E Dowell, Shelby D Melton, Chunfa Jie, William C Putnam, Thai H Pham, David H Wang, Wei Zhang, Ankur S Bhagwath, Zeeshan Ramzan, Taylor A Williams, Indhumathy Subramaniyan, Vindhya Edpuganti, Raja Reddy Kallem, Kerry B Dunbar, Peiguo Ding, Ke Gong, Samuel A Geurkink, Muhammad S Beg, James Kim, Qiuyang Zhang, Amyn A Habib, Sung-Hee Choi, Ritu Lapsiwala, Gayathri Bhagwath, Jonathan E Dowell, Shelby D Melton, Chunfa Jie, William C Putnam, Thai H Pham, David H Wang
Abstract
Itraconazole, an FDA-approved antifungal, has antitumor activity against a variety of cancers. We sought to determine the effects of itraconazole on esophageal cancer and elucidate its mechanism of action. Itraconazole inhibited cell proliferation and induced G1-phase cell-cycle arrest in esophageal squamous cell carcinoma and adenocarcinoma cell lines. Using an unbiased kinase array, we found that itraconazole downregulated protein kinase AKT phosphorylation in OE33 esophageal adenocarcinoma cells. Itraconazole also decreased phosphorylation of downstream ribosomal protein S6, transcriptional expression of the upstream receptor tyrosine kinase HER2, and phosphorylation of upstream PI3K in esophageal cancer cells. Lapatinib, a tyrosine kinase inhibitor that targets HER2, and siRNA-mediated knockdown of HER2 similarly suppressed cancer cell growth in vitro Itraconazole significantly inhibited growth of OE33-derived flank xenografts in mice with detectable levels of itraconazole and its primary metabolite, hydroxyitraconazole, in esophagi and tumors. HER2 total protein and phosphorylation of AKT and S6 proteins were decreased in xenografts from itraconazole-treated mice compared to xenografts from placebo-treated mice. In an early phase I clinical trial (NCT02749513) in patients with esophageal cancer, itraconazole decreased HER2 total protein expression and phosphorylation of AKT and S6 proteins in tumors. These data demonstrate that itraconazole has potent antitumor properties in esophageal cancer, partially through blockade of HER2/AKT signaling.
©2021 The Authors; Published by the American Association for Cancer Research.
Figures
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
- Dubecz A, Gall I, Solymosi N, Schweigert M, Peters JH, Feith M, et al. . Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 2012;7:443–7.
- Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med 2014;371:2499–509.
- Zhang W, Wang DH. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease? Dig Dis Sci 2018;63:2005–12.
- Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. . Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019;17:855–83.
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97-X.
- Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31–9.
- Moehler MH, Janjigian YY, Adenis A, Aucoin J-S, Boku N, Chau I, et al. . CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer. J Clin Oncol 2018;36(4_suppl):TPS192–TPS.
- Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. . Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506–17.
- Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, et al. . KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol 2019;15:1057–66.
- Kurosawa M, Okabe M, Hara N, Kawamura K, Suzuki S, Sakurada K, et al. . Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann Hematol 1996;72:17–21.
- Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 1999;22:1355–9.
- Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr., Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007;2:263–70.
- Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. . Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388–99.
- Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience 2015;9:521.
- Pounds R, Leonard S, Dawson C, Kehoe S. Repurposing itraconazole for the treatment of cancer. Oncol Lett 2017;14:2587–97.
- Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. . Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014;32:745–51.
- Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, et al. . Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 2013;18:163–73.
- Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, et al. . Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 2013;8:619–23.
- Gerber DE, Putnam WC, Fattah FJ, Kernstine KH, Brekken RA, Pedrosa I, et al. . Concentration-dependent early antivascular and antitumor effects of itraconazole in non-small cell lung cancer. Clin Cancer Res 2020;26:6017–27.
- Tsubamoto H, Sonoda T, Inoue K. Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer. Anticancer Res 2014;34:3839–44.
- Tsubamoto H, Sonoda T, Yamasaki M, Inoue K. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer. Anticancer Res 2014;34:2481–7.
- Tsubamoto H, Sonoda T, Ikuta S, Tani S, Inoue K, Yamanaka N. Combination chemotherapy with itraconazole for treating metastatic pancreatic cancer in the second-line or additional setting. Anticancer Res 2015;35:4191–6.
- Chen MB, Liu YY, Xing ZY, Zhang ZQ, Jiang Q, Lu PH, et al. . Itraconazole-induced inhibition on human esophageal cancer cell growth requires AMPK activation. Mol Cancer Ther 2018;17:1229–39.
- Kelly RJ, Ansari AM, Miyashita T, Zahurak M, Lay F, Ahmed AK, et al. . Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma. Ann Surg 2021;273:e206–13.
- Zhang Q, Agoston AT, Pham TH, Zhang W, Zhang X, Huo X, et al. . Acidic bile salts induce epithelial to mesenchymal transition via VEGF signaling in non-neoplastic Barrett's cells. Gastroenterology 2019;156:130–44.
- Zhang W, Hong S, Maniar KP, Cheng S, Jie C, Rademaker AW, et al. . KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8. Oncogene 2016;35:5565–75.
- Zhang W, Williams TA, Bhagwath AS, Hiermann JS, Peacock CD, Watkins DN, et al. . GEAMP, a novel gastroesophageal junction carcinoma cell line derived from a malignant pleural effusion. Lab Invest 2020;100:16–26.
- Zhang W, Zeng X, Briggs KJ, Beaty R, Simons B, Chiu Yen RW, et al. . A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 2010;29:2467–76.
- Pham TH, Melton SD, McLaren PJ, Mokdad AA, Huerta S, Wang DH, et al. . Laparoscopic ischemic conditioning of the stomach increases neovascularization of the gastric conduit in patients undergoing esophagectomy for cancer. J Surg Oncol 2017;116:391–7.
- Hu Q, Hou YC, Huang J, Fang JY, Xiong H. Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells. J Exp Clin Cancer Res 2017;36:50.
- Wang X, Wei S, Zhao Y, Shi C, Liu P, Zhang C, et al. . Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death. Cancer Lett 2017;385:128–36.
- Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489–501.
- Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 2020;20:74–88.
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098–101.
- Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144:5179–83.
- Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–8.
- Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014:852748.
- Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. . Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol 2012;19:757–65.
- Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, et al. . Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011;9:830–87.
- Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. . Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 2015;13:194–227.
- Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751–8.
- Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. . Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1364–8.
- Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women's Hospital, Broad Institute et al.Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169–75.
- Chen XX, Zhong Q, Liu Y, Yan SM, Chen ZH, Jin SZ, et al. . Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Nat Commun 2017;8:524.
- Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, et al. . Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget 2017;8:38755–66.
- Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol 2016;7:158–65.
- Zhang Q, Yu C, Peng S, Xu H, Wright E, Zhang X, et al. . Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. Gastroenterology 2014;146:461–72.
Source: PubMed